Dansk | English


Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment

August 09, 2016 09:00 AM Eastern Daylight Time

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, today announced the final closing of its Series C financing bringing an additional $10 million into the company and completing the Series C at $48.5 million. Proceeds from the financing will be used to advance development of Iconic’s lead molecule ICON-1 in retinal diseases as well begin clinical trials in ocular melanoma, Iconic’s first oncology indication. The final closing included new investor Xeraya Capital. Xeraya joins existing investors MPM Capital, HBM Healthcare Investments, H.I.G. BioHealth Partners, Lundbeckfonden Ventures, Cormorant Asset Management, and Osage University Partners in the Series C capital raise.

Vtesse Secures Additional $17 Million in Series A Extension to Support Further Product Development and Expand the Ongoing Clinical Trial of VTS-270 for the Treatment of Niemann-Pick Type C1 Disease

Investment Supports Further Product/Technology Improvements and Expanded Access to the Company's Global, Pivotal Study

Clinicians Are Now Enrolling Patients at Sites in France, Spain and Turkey in Addition to US, UK and Germany

GAITHERSBURG, Md., July 25, 2016 /PRNewswire/ -- Vtesse, Inc., a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, announced today that it has secured $17 million in additional Series A funding in support of its global, pivotal clinical trial of VTS-270 for Niemann-Pick Type C1 disease ("NPC"). 

Supernus Pharmaceuticals Founder and CEO Jack Khattar joins scPharmaceuticals Board of Directors
LEXINGTON, Mass., July 12, 2016 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today that Jack A. Khattar has been appointed to scPharmaceuticals’ board of directors.
Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev
(NEW YORK and OXFORD, UK – June 30, 2016) - Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab) to treat a range of tumor types in late-stage cancer patients.
Ziarco Pharma Ltd: Ziarco reports positive Phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients

Clinically and statistically significant reduction in signs and symptoms of moderate to severe atopic dermatitis

- 50% (p=0.01) improvement on the eczema severity score (EASI) at week 8

- ZPL-389 was well tolerated with a safety profile comparable to placebo

- Phase 2b study to commence in H2 2016

- Full study data presented at European Academy of Allergy and Clinical Immunology 35th Annual Congress 2016 Vienna, Austria on 12 June

Former Head of R&D at Orexigen Therapeutics and Therapeutic Area Head for Nephrology at Amgen appointed as CMO 

CMO appointment and launch of US subsidiary are significant steps in establishing a US presence
Palma de Mallorca, Spain, 07 June 2016 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces the appointment of Dr Preston S. Klassen, MD, MHS as its Chief Medical Officer and the launch of its US Subsidiary Sanifit Inc., based in San Diego, USA.
BONESUPPORT™ Announces Nature Publication Of Pre-Clinical Study Highlighting CERAMENT™’s Attractive Bone Remodeling Properties and as a Local Drug Delivery Platform for Bone Disease
Lund, Sweden, 1 June  2016  – BONESUPPORT AB, an emerging leader in innovative injectable bioresorbable bone graft substitute products to treat bone voids caused by trauma, infection, disease or related surgery today announced  the publication of a paper in  Nature Scientific Reports: A Biphasic Calcium Sulphate Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone (Raina, D et al., reference below).The paper covers a pre-clinical study which demonstrated that CERAMENT™ loaded with a combination of recombinant human bone morphogenic protein 2 (“rhBMP-2”) plus zoledronic acid (“ZA”) in very low doses was able to quantitatively and qualitatively generate a higher amount of mineralized bone volume. The study also showed In vivo that the mineralized volume was significantly higher when CERAMENT™ was combined with rhBMP-2 and ZA (21.4±5.5mm³) as compared to CERAMENT™ in combination with just rhBMP-2 (10.9±2.1mm³). Raina, D. et al.
Vtesse Advances Phase 2b/3 Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease with Dose Selection for Evaluation in Second and Final Portion of Trial and Expansion into Europe
GAITHERSBURG, Md., May 23, 2016 /PRNewswire/ -- Vtesse, Inc. announced today that the dose-finding portion of the company's global, pivotal Phase 2b/3 clinical trial for its lead investigational product, VTS-270, for treatment of Niemann-Pick Type C1 Disease (NPC) is now complete, and a dose level for further testing has been selected by an independent dose selection committee (DSC). Vtesse's ongoing Phase 2b/3 prospective, randomized, double-blind, sham-controlled trial is a three-part, efficacy and safety trial of VTS-270, administered by the lumbar intrathecal (IT) route every two weeks. VTS-270 is based on a specific, well-characterized composition of 2-hydroxypropyl-beta-cyclodextrin.  
Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead Compound ZPL-389

50% (p=0.01) improvement on EASI score at week 8

- Full data to be presented at the EAACI Congress, 12 June 2016, Vienna, Austria in a Late Breaking Oral Session

Discovery Park, Sandwich, UK, 16 May, 2016 - Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs for the treatment of inflammatory skin disorders, is today pleased to announce positive top line results from its first Phase 2a proof of concept study of ZPL-389 for the treatment of moderate to severe atopic dermatitis.

First Data from largest colposcopy trial


DySIS Medical Ltd. (DySIS), an innovative women’s health company that offers a new cervical imaging technology (dynamic spectral imaging) for women with abnormal Pap smears, announced today it will present initial findings from the IMproved PRactice Outcomes and Value Excellence in Colposcopy (IMPROVE-COLPO) at the Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG), to be held in Washington, D.C., May 14-17.

Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste